CRISPR Therapeutics Files 8-K for 'Other Event' on Jan 16, 2024
Ticker: CRSP · Form: 8-K · Filed: Jan 16, 2024 · CIK: 1674416
Complexity: simple
Sentiment: neutral
Topics: administrative, compliance, 8-K
TL;DR
**CRSP filed a routine 8-K, no major news, just administrative updates.**
AI Summary
CRISPR Therapeutics AG filed an 8-K on January 16, 2024, to report an "Other Event." This filing primarily serves to update administrative information, confirming its status as a publicly traded company on The Nasdaq Global Market under the ticker CRSP. For investors, this filing is largely procedural and does not contain new material financial or operational news that would immediately impact the stock price, but it reaffirms the company's compliance with SEC reporting requirements.
Why It Matters
This filing is a routine administrative update, indicating ongoing compliance with SEC regulations, which is important for maintaining investor confidence and market transparency.
Risk Assessment
Risk Level: low — This 8-K filing is purely administrative and does not introduce any new financial or operational risks to the company.
Analyst Insight
A smart investor would recognize this as a non-material administrative filing and would not make any immediate trading decisions based solely on this 8-K. Instead, they would focus on the company's clinical trial progress, regulatory approvals, and financial performance reported in other filings.
Key Numbers
- 001-37923 — Commission File Number (identifies the company's registration with the SEC)
- 2024-01-16 — Date of Report (indicates when the reported event occurred)
- CHF 0.03 — Nominal Value per Common Share (the stated par value of the company's shares)
Key Players & Entities
- CRISPR Therapeutics AG (company) — the registrant filing the 8-K
- The Nasdaq Global Market (company) — the exchange where CRSP common shares are registered
- CRSP (company) — the trading symbol for CRISPR Therapeutics AG
- January 16, 2024 (date) — date of earliest event reported and filing date
- CHF 0.03 (dollar_amount) — nominal value of common shares
Forward-Looking Statements
- CRISPR Therapeutics AG will continue to file routine administrative 8-K forms without significant new disclosures. (CRISPR Therapeutics AG) — high confidence, target: 2024-12-31
FAQ
What is the purpose of this 8-K filing by CRISPR Therapeutics AG?
This 8-K filing by CRISPR Therapeutics AG is categorized under 'Other Events' and primarily serves as a current report to the SEC, confirming administrative details such as its registration on The Nasdaq Global Market and its compliance with reporting requirements as of January 16, 2024.
On what date was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 16, 2024.
What is the trading symbol and the exchange where CRISPR Therapeutics AG's common shares are registered?
CRISPR Therapeutics AG's common shares are registered under the trading symbol CRSP on The Nasdaq Global Market.
What is the nominal value of CRISPR Therapeutics AG's common shares as stated in the filing?
The nominal value of CRISPR Therapeutics AG's common shares is CHF 0.03.
Does this 8-K filing indicate that CRISPR Therapeutics AG is an emerging growth company?
No, the filing indicates with a checkbox that CRISPR Therapeutics AG is NOT an emerging growth company, as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 385 words · 2 min read · ~1 pages · Grade level 12.4 · Accepted 2024-01-16 16:11:36
Filing Documents
- crsp-20240116.htm (8-K) — 37KB
- 0000950170-24-004616.txt ( ) — 145KB
- crsp-20240116.xsd (EX-101.SCH) — 25KB
- crsp-20240116_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On January 16, 2024, the U.S. Food and Drug Administration approved CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia in patients 12 years and older.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CRISPR Therapeutics AG Date: January 16, 2024 By: /s/ Samarth Kulkarni Samarth Kulkarni, Ph.D. Chief Executive Officer